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1. Introduction 
1.1 Concept of Non-Dimensional Physiological Indices (NDPIs) or Physiological 
Numbers (PHYNs) 
In this chapter, we are providing a new concept in physiological systems analysis1(or organ 
systems analysis), in terms of nondimensional physiological indices (or physiological system 
numbers), for qualifying patient health and disease status as well as patient improvement. 
The concept of a Nondimensional Physiological Index (or NDPI) is quite new, and has been 
adopted from Engineering, wherein nondimensional numbers (made up of several terms) 
are employed to characterize disturbance phenomena. For example, in a cardiovascular 
fluid-flow regime, the Reynold’s number 
 
re
VDN ρ µ=  
(1) 
is employed to characterize the conditions when Nreexceeds a certain critical value, at which 
laminar blood flow changes to turbulent flow. This can occur in the ascending aorta when 
either the aortic valve is stenotic (giving rise to murmurs) or in the case of anaemia 
(decreased blood viscosity). 
In physiological medicine, the use of nondimensional indices or numbers can provide a 
generalized approach by which unification or integration of a number of isolated but 
related events into one nondimensional physiological index (NDPI)can help to 
characterize an abnormal state associated with a particular organ or physiological system 
or an anatomical structure. The evaluation of the distribution of the values of such 
NDPI(s), in a big patient-population, can then enable us to designate normal and 
disordered ranges of NDPI, with a critical value of NDPI separating these two ranges. In 
this way, NDPI(s) can help us to formulate patient-health indices (PHIs), not only to 
facilitate differential diagnosis of patients but to assess the severity of the disease or 
disorder as well[1,2]. 
                                                                 
This chapter is based on the author’s paper: Nondimensional Indices for Medical Assassment, in 
Mechanics in Medicine and Biology, Vol 9, No 4, 2009, World Scientific Publishers. 
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In medicine, assessment tests are carried out to (i) determine the functional performance of 
an organ (such as the heart) or a physiological system (such as the glucose-insulin 
regulatory system), and (ii) diagnose an anatomical structure’s pathological condition, such 
as a calcified mitral valve or osteoporosis. In many cases, the medical tests do not 
quantifiably assess the concerned oral or physiological system and do not quantifiably 
diagnose the pathological condition of the anatomical structures. 
So for some conventional tests (such as the Treadmill test to assess heart function, and Oral 
glucose tolerance test to diagnose diabetes), we have developed NDPI (s) made up of 
parameters that (i) are associated with the methodology of the tests, and (ii) characterise the 
function and disease states of organs (such as the heart) and physiological systems (such as 
the glucose-insulin regulatory system). We have also developed some new medical tests to 
detect anatomical structures’ pathology (such as arteriosclerosis and mitral valve 
calcification) in terms of NDPI (s) to characterize their pathological state. In this chapter, we 
have formulated nine medical tests and their associated NDPI s).  
We would like that the NDPI (s) developed in this chapter, for both conventional tests as 
well as newly formulated tests, can be applied clinically to set the stage for more accurate 
medical assessment. These medical tests and their associated NDPI (s) need to be applied to 
large patient population, to determine the normal and abnormal (or pathological) ranges of 
these NDPI (s). This will enable incorporation of our newly formulated NDPI (s) into 
medical practice. 
2. Cardiac contractility index 
Let us provide an example of one of our NDPI(s) which has been clinically employed. In 
cardiology, the index (dP/dt)max (of maximum rate-of-increase of left ventricular chamber 
pressure)  has been traditionally employed as a measure of cardiac contractility. Diminished 
cardiac contractility affects cardiac output and can lead to heart failure. Hence, this is an 
important index of left ventricle (LV) functional capability. However, this index requires the 
invasive measurement of LV chamber pressure by catheterization. So, we developed an 
alternative cardiac contractibility index in terms of the normalised wall stress of the LV with 
respect to LV chamber pressure, *= /P.  Now, corresponding to (dP/dt)max, we have 
formulated the cardiac contractility index (CCI) of dσ*/dtmax, which does not require the 
measurement of LV chamber pressure. This contractility index can be conveniently 
expressed in terms of LV chamber cavity volume (V) and myocardial volume (Vm), as 
indicated in Ref 4. as well as in this section 5 of chapter 34 on how cardiac disease states 
cause decreased contractility and how surgical ventricular restoration improves  
contractility. By employing a thick-walled spherical LV model with inner and outer radii 
riand re, we can express LV pressure-normalised wall stress ( *) as [3,4]: 
 i
3 1
* (r r )
2 2m
V
V
σ
⎛ ⎞
= = +⎜ ⎟⎜ ⎟⎝ ⎠
 (2) 
where V(=4πri3/3) denotes LV volume, and Vm(=4π(re3-ri3)/3) denotes LV myocardial 
volume. Then by differentiating *σ with respect to time, we get the expression for CCI as: 
 max
max max
( ) 3
, *
2 m
d p dV
CCI d dt
dt V dt
θσσ
⎛ ⎞
= = ⎜ ⎟⎝ ⎠  (3a)  
σ σ
σ
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At the National Heart Center (in Singapore Gerneral Hospital), we have validated dσ*/dtmax 
against dP/dtmax in subjects with disparate ventricular function (as illustrated by figure 6 in 
chapter 34) and demonstrated the index’s load independence. For normal subjects, this 
index value range is 4 – 4.5 s-1. We have also successfully employed this (dσ*/dt)max 
contractility index to assess (i) reduced LV contractility in ischemic cardiomyopathy patients 
in the range of 2. 64 ± 0.74s-1 and (ii) improved contractility in the range of 3.32 ± 0.73 s-1 
following surgical ventricular restoration [5]. 
We could even divide this CCI index by the heart rate, and make it nondimensional, as: 
 ( ) ( )12  100  [ * / ] /  HR inmaxCCI d dt sσ −− =  (3b) 
For normal hearts (with HR in the range of 60-80 per min), this index would give values in 
the range of 300-500, while for ischemic cardiomyopathic hearts (and HR greater than 100 
per min) this index would be in the range of 200 and below. This CCI-2 index would even 
more reliably represent cardiac contractility, by more distinctly differentiating ischemic and 
infracted hearts from normal hearts. 
3. Assessing cardiac fitness and heart function 
In this section, we show how the conventional Treadmill test can be formulated in 
biomedical engineering terms, to derive a cardiac fitness index to detect a malfunctioning 
heart due to, for instance, an infarcted heart caused by coronary occlusion.  
The Treadmill test’s cardiac fitness model consists of a first-order differential-equation system 
models, describing the heart rate (HR) response (y) to exertion (exercise, jogging, etc.) 
monitored in terms of a constant work-load or power (W) , where y is  defined as follows [6,2] 
 
( ) ( )
( )
HR t HR rest
y
HR rest
−
=
 
(4) 
In a Treadmill test, the subject is asked to exercise on the treadmill for a period of time, 
te(min). During this period, the HR(t) (and hence y) is monitored. Now we develop a model 
to simulate (i) the HR(t) response to  during exercise, i.e. t <te and (ii) thereafter for HR(t) 
decay after the termination of exercise (as illustrated in figure 1). 
The DEq for y response to exercise on the treadmill at a constant work-load or power 
exerted (W) is given by   
1 0
dy
k y C W
dt
+ = , for t ≤te 
 
2 0
dy
k y
dt
+ = , for t ≥te (5) 
where (1) k1 and k2 are the model parameters, and (2) C0 is a conversion factor to express W 
in the same units as the other terms of the equation. The y solutions to equations (5) are 
represented by:   
     ( )10
1
1 k t
C W
y e
k
−
= − , for et t≤  during the exercise
( )
( )
1
1
1
1 e
k t
e
k t
y e
e
−
−
−
=
−
 (6) 
www.intechopen.com
 Biomedical Science, Engineering and Technology 854 
        2 ( )ek t tey y e
− −
= , for t ≥te   during the recovery period when W=0  (7) 
where ye = y(t=te), and k1 andk2 are the model parameters which can serve as cardiac fitness 
parameters ( in units of min-1). 
We now carry out parametric simulation to the monitored HR data on treadmill, by making 
equations (6 and 7) fit the HR data. The parameters k1 and k2 can be combined into a non-
dimensional fitness  index CFI given by: 
 21 2 eCFI k k t=  (8) 
 
 
Fig. 1. Sample subject’s  monitored y versus t data  (Adopted from Ref 6: Lim GeokHian, 
Dhanjoo N. Ghista, Koo TseYoong, John Tan Cher Chat, Philip EngTiew& Loo Chian Min; 
International Journal of Computer Application in Technology: Biomedical Engineering & Computing 
Special Issue, Vol 21, No 1/2, 2004.). 
According to this formulation of CFI, for subjects exercised at identical workloads, a 
healthier subjects would have (1) greater k1 (i.e., slower rate of increase of HR during 
exercise), (2) greater k2 (i.e., faster rate of decrease of HR following exercise), (3) greater 
te(i.e., exercise endurance); and hence (4) higher value of CFI. 
We need to evaluate CFI for a big spectrum of patients, and then compute its distribution 
curve, to determine the efficacy of this index, in order to yield distinct separation of CFI 
ranges for healthy subjects and cardiac patients. This CFI can then also be employed to 
assess improvement in cardiac fitness following cardiac rehabilitation regime. 
4. Lung ventilation Index to detect lung disorders 
Herein, we are formulating a new test involving: (i) monitoring of lung volume by means of 
a spirometer; (ii) the biomedical engineering model of the lung volume response to lung 
inflation driving pressure, which is equal to mouth pressure minus pleural pressure 
monitored by placing a balloon catheter transducer through the nose into the esophagus; 
(iii) derivation of the lung ventilation index made up of the parameters of the lung volume 
response model, and  its employment to detect lung disorders.  
The differential equation of lung ventilation volume (V) response to lung inflation-pressure 
(PL) is given (as illustrated in figure 2) by [1, 2]: 
 
( ) ( )0
1 1 2
@ exp
cos cos
D p p
dV V
R P P P P end iration
dt C
P P t P tω ω
+ = = − − −
= − +
 (9)  
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wherein V is the lung volume in litres (L), P0 is the presence at the mouth(in cm H20) and Pp is 
the pleural pressure (in cm H20).  The right-hand side terms constitute the fourier series 
representation of the lung driving pressure (PD) in cm H20, R is the resistance to airflow (in cm 
H2O· S · L-1), C is the lung compliance (in L/cm H2O), and P1 and P2 are the magnitudes of 
fourier series terms of the lung driving (oscillatory) pressure PD  [ = (mouth-pressure minus 
pleural-pressure), with respect to the absolute value of end-expiratory pleural pressure]. 
For a typical PD cyclic pressure profile (Fig.2), represented by   
P1 = 1.84cm H20,       P2 = 3.16cm H20,      ω = 0.5πs-1,  
the solution to the above Eq. (9) is given by 
 
( ) ( ) ( )
( ) ( ) ( )
1 1 22 2 2 2
2 2
1 22 2
cos sin sin cos
1
1 1
1 2
1
t
t
t t
V P C e P C P C
e
P C P C
τ
τ
ω ωτ ωτ ω ωτ ωτ
ω τ ω τ
ω τ ωτ
ω τ
−
−
+ +
= − − +
+ +
⎡ ⎤+ + +⎢ ⎥⎣ ⎦+
 (10) 
wherein τ = RC. By fitting this lung volume solution to the clinically monitored lung-
volume parameters, we get: R = 1.24(cm H20) sL-1, C = 0.21L(cm H20)-1.  
Now, then, let us formulate the nondimensional lung ventilator performance index (LVPI-1) 
given by:  
 LVPI-1 = RC (BR per min),  (11) 
wherein BR, the breathing rate =30ω/π per min = 15/min or 0.25/sec for the data provided 
in Fig.2. For our case study, the value of LVPI is 3.9. 
 
 
 
              
( ) ( ) ( )
 
      
     @
     @
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Fig. 2. Lung Ventilation Lumped parameter model. 
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Fig. 3. Lung pressure and volume as functions for normal breathing; note that the pressure 
extremes occur before the volume extremes. 
Let us now see how lung disease will influence R, C and hence LVPI. For instance in 
emphysema, the destruction of lung tissue will produce a more compliant lung and hence a 
larger value of C = 0.5L (cm H20)-1, say, yielding a value of LVPI of about 10. In asthma, there is 
increased airway resistance (due to contraction of the smooth muscles around the airways) to 
say R=5(cm H20) sL-1. The breathing rate can go also go up to BR = 20/min, say. Hence, the 
value of LVPI can go up to 20. In the case of lung-congestion, due to mitral-valve disease, it 
would be important to determine LVPI, so as to serve as an indicator for determining cardiac 
condition (in end-stage heart-disease). By determining the distribution of a big patient 
population, we can determine the LVPI ranges for normal and disease states. 
Now this procedure refers to monitoring of pleural pressure (PP) by placing a balloon catheter 
transducer through the nose into the esophagus (assuming that the esophageal tube pressure 
equals the pressure in the pleural space surrounding it). So, let us now develop a procedure 
whereby we do not need to monitor pleural pressure and only need to monitor lung volume 
by means of a spirometer. For this purpose, we now identify three model parameters (P1C), 
(P2C) and . These parameters can be determined by having equation (10) match or stimulate 
the lung volume data in figure 3. We now formulate a non-invasively determinable 
nondimensional ventilator index (LVPI-2), as  
 
( ) ( )
( )( )
2
1 2
2
BR TV
LVPI
P C P C
τ
− = , TV= tidal volume (12) 
Upon evaluating LVPI-2 for a number of patients, we can determine its ranges for normal 
and disease states, to employ it diagnostically. We can expect that subjects with chronic 
obstructive lung disease (COPD) and asthma subjects (with a high value of R) will have a 
high value of LVPI -2, while emphysema subjects (with high value of C) will have a low 
value of LVPI -2. So in the distribution curve of LVPI -2, emphysema subjects will be at the 
τ
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low end of distribution curve, COPD and asthma subjects will be at the high end of the 
distribution curve, while normal subjects will be in the middle of the distribution curve. 
Now for noninvasive assessment of lung disease state in terms of lung compliance (C) and 
resistance-to-flow (R), we need to be able to determine lung pressure (PD) function 
noninvasively. In section 4 of chapter 36 on lung ventilation modeling for assessment of 
lung station we have shown how we can determine the lung driving pressure functional 
parameters along with C and R in termo of the monitored values of lung volume. 
We have also formulated a non-dimensional lung ventilatory index (equation 30) in terms of 
R, C, tidal volume (TV), lung pressure value at TV and breating rate. After this index is 
evaluated for different disease states, it will enable reliable noninvasure assessment of lung 
status.   
5. Diabetes diagnosis from oral-glucose-tolerance test by means of a 
diabetes index (OGTT) 
In this section, we have developed a biomedical engineering model for OGTT and 
demonstrated how it can be applied to OGTT data in (figure 4) to formulate and evaluate a 
diabetic NDPI, to more reliably diagnose diabetes.  
For oral-glucose tolerance test simulation (entailing digestive and blood-pool chambers), the 
differential equation, and governing blood-glucose response (y) to oral ingestion of glucose 
bolus (G, gm L-1hr-1), given by[7]: 
( )22 ny" Ay' y G tω δ+ + = ; y in gL-1, G in gL-1hr-1 
 ( )dy" T y' y G tλ λ δ+ + =  (13) 
where (= 1/2) is the natural oscillation-frequency of the system, A is the attenuation or 
damping constant of the system,  = ( -A2)1/2 is the (angular) frequency of damped 
oscillation of the system, (2A/Td = ) is the parameter representing regulation proportional 
to rate-of–change of glucose concentration (y), and λTd  is the parameter representing 
regulation proportional to rate-of-change of glucose concentration ( ). 
Figure 4 illustrates the OGTT data for typical normal and diabetic subjects. For an impulse 
glucose ingestion input, we can simulate a normal patient’s blood-glucose concentration 
databy means of the solution of the Oral glucoseregulatory (second-order system) model, as 
an under-dampedglucose-concentration response curve, given by: 
 ( ) sin , AtGy t e tω
ω
−
⎛ ⎞
= ⎜ ⎟⎝ ⎠  (14) 
When this solution is made to simulate the normal subjects OGTT data, we get A=1.4 hr-1, ω 
= 0.775 rad/hr, G = 1.04 gL-1 hr−1, =2.6 hr−2, Td= 1.08 hr. The simulated curve is also 
depicted in figure 4. 
For a potential diabetic subject, we adopt the solution of the above Differential equation 
model, as an over-damped response function: 
 
( ) sinh . AtBy t e tω
ω
−
⎛ ⎞
= ⎜ ⎟⎝ ⎠  
(15)  
n
ω λ
ω 2
n
ω
λ 2
n
ω
y′
λ
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Fig. 4. OGTT Response Curves: A = 1.4hr−1 (i.e. higher damping-coefficient value) for the 
normal subject for the diabetic patient, A = 0.808 hr−1. Also, for the normal subject, the 
regulation parameters λ and λTd  are 2.6 hr−2 and 2.8 hr−1 respectively, which are greater 
than their values of 0.26 hr−2  and 1.62 hr−1 for the diabetic subject. Further, the non-
dimensional number for the normal subject is 1.3, compared to 4.9 for the diabetic subject. 
For this OGTT data simulated function (figure 4), the parameters values are: A = 0.808 hr−1, 
ω = 0.622 rad hr−1, G = 2.95 gL-1 hr−1, = 0.266 hr−2, Td = 6.08 hr. 
Now, we come to the interesting part of this model, by formulating the nondimensional 
Diabetes index (DBI) as: 
 
2 2
2
2 2
.      d
n
A A
DBI AT λ ω
= = =  (16) 
The value of DBI for the normal subject is found to be 1.5, whereas that for the diabetic 
subject is  4.9.  It is further seen (in our initial clinical tests) that DBI for normal subjects is < 
1.6, while the DBI for diabetic patients is > 4.5. This is a testimony of the efficacy of the 
model, and especially for the nondimensionalDBI.  
Now between these two cases of under-damped and over-damped responses, we have the 
case of a critically-damped response, for which the solution of the OGTT model differential 
equation (13) is given by  
2 2( ) ,  for which 0,  and A = =At ny t Gte ω λ ω−= =  
This critically-damped response corresponds to cases of subjects who are not distinctly 
normal or diabetic but are at the risk of becoming diabetic. It can be seen that DBI for the 
critically-damped response is 2. So, in the distribution curve of DBI ( to be obtained by 
applying this method to a large patient population), the DBI range of less than 1.6 would 
λ
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refer to normal subjects, the range of greater than 4.5 would refer to diabetic subjects, and 
range of 2-4 would refer to subjects at risk of becoming diabetic. This would make the use of 
the model and the DBI to be  so convenient for the physician. 
6. Characterization of arterial stiffness or arteriosclerosis by means of NDI 
In this section, we are formulating a new test to noninvasively determine the arterial 
constitutive property so as to be able to diagnose arteriosclerosis.  
For a circular cylindrical arterial tube of radius a and wall-thickness h, we can express the 
stress ߪand elastic-modulus E, as follows: 
 ( )22 2130 / ;   ;   0PWV aPa Pa N m E E E m
h h h
ρ
σ σ= = = = +  (17) 
in terms of (i) the arterial dimensions a and h, the auscultatory (or automatedly) measurable 
diastolic pressure (P) and pulse-wave velocity (PWV) determined by ultrasound [8]. The 
table below then depicts the computed values of ߪ	and E at four independent times.  
 
P (mmHg) PMV  (m/s) A (mm) h (mm) 
2
N
E
m
⎡ ⎤⎢ ⎥⎣ ⎦  2
N
m
σ
⎡ ⎤⎢ ⎥⎣ ⎦  
80 5.3 4.1 1.10 2.13 x 105 3.38 x 104 
85 5.4 4.5 1 2.6 x 105 4.97 x 104 
90 5.42 5.0 0.90 3.01 x 105 5.97 x 104 
95 5.5 5.0 0.90 3.38 x 105 6.68 x 104 
Table 1. 
 ( ) ( )2 25Result :   4.2 0.5X10  = . oN m N mE mo + Eσ= +  (18) 
We will now define the arteriosclerotic non-dimensional index 
 ( )0 mean diastolic pressureART NDI mE− =  (19) 
For the above patient, the value of the ART – NDI is 
 
( )( )
( )
2
2
54.2 0.5X10
17.6  
87X137
N
ART NDI
m
N m
− = =  (20) 
and will be much higher for arteriosclerotic patients, which we will determine by 
conducting clinical tests-applications of this analysis. This ART-NDI to detect 
arteriosclerosis requires echocardiographic determination of arterial dimensions and 
PWV[8], and auscultatory diastolic  pressure. 
7. To non-invasively determine aortic elasticity (m), peripheral resistance (R), 
aortic NDI, and aortic pressure profile 
Herein, we have developed the analysis to noninvasively determine the aortic pressure 
profile, which can have significant diagnostic applications. This analysis is also employed to 
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determine (i) aortic volume elasticity parameter m (=dP/dV), (ii) periphal resistance 
parameters R=P(pressure)/Q(flow rate), and (iii) the aortic property NDPI, given by aortic 
number. Based on the aorta fluid mechanics model (figure 5), we obtain: 
 ( ) ( ) ( ) ( ) /dV I t Q t I t P t R
dt
= − = −  (21-a) 
 
dP dP dV dV
m
dt dV dt dt
= =  (21-b) 
We can then  put down the aortic pressure (P) response to aortic inflow-rate or LV outflow-
rate I(t) as follows [9,1] : 
 ( ) ; dP P mI t
dt
λ+ =  (22) 
wherein, ݉ ൌ  Volume elasticity of aorta (in Pa/m3), and ߣ ൌ ሺ݉ ܴ⁄ ሻ	in	sିଵ. 
The LV outflow-rate is represented as: 
 
( ) ( )sin( / ) ( / 2)sin(2 / ) ,     0  ( )
     0;    
s s s
s
I t A t t A t t < t < t systole
t > t (diastole)
pi pi= +
=
 (23) 
 
 
Fig. 5. To derive the equation for Aortic-pressure response to the stroke-volume or LV 
output rate I(t). 
If ts= 0.35s, and Stroke vol(SV) is known (from, say, echocardiography), then we have 
 ( ) ( ) ( )
0
( )sin 2 sin 2
st
s sA t t A t t SVpi pi⎡ ⎤+ =⎣ ⎦∫  (24) 
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wherein ( ) / 2 sA SV tpi=  
 
So if   71.4 ,   then   320 .SV cc A cc s= =
 (25) 
The solutions of Eq. (22) for the aortic diastolic and systolic periods are obtained as follows 
[9,1]: 
Aortic Diastolic Pressure expression (fig 6): 
 ( )
( )
2
1
( )
1
( ) ;         
       
( ) ,      0.8 .
s
z
t t
d
T t
d
P t P e P pressure at start of diastole
P at t = T pressure at end of systolic phase
P t P e wherein T s
λ
λ
− −
−
= =
= =
∴ = =
 (26) 
This ௗܲሺݐሻ function is equal to ଶܲ at t= ts  (at the end of systolic phase)  and ଵܲ at t=T (end of 
diastotic phase). 
Aortic Systolic Pressure expression (fig 6): 
 
2 2
2
1 2 2 2
2
2
sin cos
sin 2 2 cos2
            ;     . 
2 4
2
( )
4
s
s
tAm t t
mA t t
Am
P t P e m
t
Aλ
λ ω ω ω
λ ω
λ ω ω ω pi
ω
λ
ω
λ λ
ω
ω
ω ω
−
−⎛ ⎞⎜ ⎟
+⎝
⎛ ⎞
= + + +⎜ ⎟
+ +⎝ ⎠
−⎛ ⎞
+ =⎜ ⎟⎝ ⎠
⎠
+
 (27) 
This Ps(t) function is maximum at t=tm, and equal to the monitored systolic auscultatory 
pressure P3 = 118mmHg. 
We now (i) incorporate into Eqs. (26) and (27) the auscultatory data of P1(80mmHg) and P3 
(118mmHg) with T = 0.8 s, and us=0.35s, as well as (ii) invoke continuityin diastolic and 
systolic pressure expressions, to (iii) put down and solve the following three equations (in 
three unknowns: m, λand tm which Ps= P2): 
 ( ) ( )at 0.35s at 0.35s   d s s sP P= = =  (28) 
 
( )at
0 s mdP t
dt
=  (29) 
 ( ) ( )= 118mmHg   s m 3P t = t = P  (30) 
to obtain: λ=0.66 s-1, m = 0.78 mmHg cm-3, R = 1.18mmHg cm-3 s, tm= 0.25 s, for T = 0.8 s. 
We now formulate the Aortic number (or index): 
 Aortic number mT/RTλ= =  (31) 
whereinλ= m/R in the governing differential equation (22), m =103 x 106 Pa m-3 , R=157x 106 
Pa m-3 s, and λ =0.66s-1 
We thereby obtain the ( )( )1 T 0.66s 0.8s 0.52.  Aortic Number λ −= = =  (32) 
In order to have a more convenient order-of-magnitude value of the Aortic number index 
(equation 31), we could employ the Aortic number = 100 (λT). In the distribution of Aortic 
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number (obtained  by applying this methodology to a large patient population), the low 
range of Aortic Number will correspond to patients with vasoconstriction, the high range of 
Aortic Number will associated with arteriosclerotic patients, and patients with normal 
healthy aorta will be in the middle of the distribution. 
Finally with the help of the evaluated parameters m and R, we can now construct the aortic 
pressure profile based on equations (26 and 27), as illustrated in figure 6. This aortic 
pressure profile can have significant diagnostic implications. As we know, in Ayurvedic 
medicine and Chinese Traditional medicine, the physician feels the pulsation of the patients 
brachial artery (just proximal to the wrist), and based on it provides diagnosis of a wide 
spectrum of diseases. Essentially, the physician is feeling the magnitude and shape of the 
arterial pressure pulse.  
Now, we have shown that we can in fact noninvasively determine the aortic pressure 
profile, which is more diagnostically indicative than the pressure pulse in the more distally 
located brachial artery. Hence, we can bring to bear this medical inferential and experiential 
knowledge to firstly characterise the magnitude and shape of the aortic pressure profile (by 
Fourier analysis), and then correlate the Fourier series parameters to the information about 
the associated disease states available from Ayurvedic and Chinese medicine systems. 
 
 
Fig. 6. Illustration of the Aortic pressure profile, based on the analysis.  The systolic phase is 
from t = 0 to t = ts = 0.35s. The diastolic phase is from t = ts = 0.35s to t = T= 0.8s.    
8. Mitral-Valve (MV) property determination for its pathology characterization 
(to provide interventional guidelines) 
Determining the in-vivo constitutive property of the mitral valve (for a quantifiable estimate 
of its calcification and degeneration) constitutes another example combining “clinical-data 
monitoring and processing” with “modelling-for-clinical diagnosis”. 
The mitral valve opens at the start of the diastolic phase when the blood from the left atrium 
fills the left ventricle (LV). At the end of the diastolic phase and at the initiation of LV 
contraction phase, the rising LV pressure and the blood flow pattern in the LV chamber 
brings the valve cusps together to close the MV, and set its cusps into vibratory motion, 
which is monitored as the First Heart sound (FHS). 
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From a biomedical engineering consideration, the mitral valve in its closed position (at the 
end of the diastolic phase) can be modelled as a semi-circular membrane, which is fixed 
along its circular edge to the heart chamber wall and supported along its straight edge by 
the chordae tendineae  (as depicted in figure 7), so that its deflection is zero along its edges 
[10,11]. In this configuration, the MV vibrates after its cusps come together to close the 
valve. The frequency of MV vibration (fmv) (as obtained from the FHS frequency spectrum) 
can be expressed in terms of the MV constitutive parameter property (E vsσ) , which conveys 
information about its health state and pathology. This methodology provide a more reliable 
and quantitative approach for detecting a pathological MV (such as owing to its leaflets 
calcification) than by merely listening to the First Heart sound ( aspractised clinically). 
To this end, we provide the expressions for determining MV stress (σ) and its elastic 
modulus (E) from the physiological data of the MV vibration its closed configuration. We 
then develop expressions for mitral valves modulus-based property E* and stress-based 
property σ *, and propose that the E* vsσ * relationship be employed to characterise mitral 
valve pathology. Alternatively, we can also track mitral valve pathological deterioration, by 
monitoring the changes in valve of m (= E/ σ ) in terms of the changes in fmv  as the valve 
pathology progresses, and determine the time for intervention of replacing the pathological 
MV by means of a prosthetic MV. 
We make use of: 
- echocardiography (to determine the mitra-valve geometry) and spectral 
phonocardiography (of the first-heart sound associated with MV vibration), to 
determine the second-peak frequency (f2) of the first heart-sound spectrum 
- along with static and dynamic (vibration) analyses of the semi-circular mitral valve 
leaflet model (held along its circular boundary), as illustrated in Fig. 7, to obtain the 
following expressions [10 & 11],  for 
Stress (σ) in the leaflet membrane  ( )
2 2
2 2
2
,
/ 2nm
f a
K
pi ρ
=  (33) 
wherein a is the radius of the semi-circular leaflet; ρ is the leaflet membrane density per unit 
area; Knm is the mth zero of the nth order Bessel function Jn(k), m (number of nodal circles = 1, 
and (number of nodal diameters)=1, and k11 = 3.832. 
 
 
Fig. 7. The mechanism of MV closure and subsequent vibration, in the genesis of the first-heart 
sound. Functional mechanics of the Mitral valve: (a) mitral valve opening at start of left 
centricular diastole; (b) as the filling left ventricle distends, traction is applied through the 
chordae tendineae  to the valve cusps, pulling them together; (c) at the start of LV systole, the 
valve cusps are sealed together by the high internal pressure and the flow pattern in the 
ventricular chamber. It is at this point in time that the mitral valve starts vibrating.  
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Modulus (E) of the leaflet membrane ( )
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2
6 2
11 0
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pi ρ ν−
=  (34) 
Wherein t = leaflet thickness, ν is the Poisson’s ratio, qo is the pressure difference across the 
leaflet at time of occurrence of the closed Mitral-valve (MV) Vibration, and Sn (the 
summation of a series) = 0.105. 
Based on eqs. (33) and (34), the nondimensional constitutive parameter (m) of the MV, is 
given by 
 ( )
6 4 2 2 2
2
42
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3 (1 )
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m
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pi ρ ν
σ
−
= =  (35) 
As a matter of interest, for the data: f2 = fmv = 100Hz, q0 = 2 mm Hg, ρ= 1.02 gm/cm3,  a = 1 
cm, t = 0.5 mm, υ = 0.5, and evaluating Sn (= 0· 0234, Eq 2· 16, Ref.2), we get σ = 2.75 x 103 
N/m2 and E=1.6x105 N/m2.  
Now, changes in MV pathology will affect its density(ρ) and thickness (t), as well as its 
modulus (E) vs stress (σ) property which we want to determine by combining FHS power-
spectrum analysis ( to determine fmv ) and 2-d echocardiographic analysis ( to determine the 
size parameter a). 
We now designate a new stress-based property (σ*) of MV (from equation 33), as 
 
2 2 2
2
*
(1.916)
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= =  (36) 
as well as a new modulus –based property (E*) of MV (from equation 34), as 
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We can now employ this E* vs. σ* relationship as a constitutive property of MV, to 
characterize and track its degeneration for timely intervention purpose. 
This technology and methodology can provide the basis for timely surgical and/ or 
replacement intervention for a diseased MV. In order to apply this analysis, we can 
determine the valvular leaflet size parameter (a) from 2-D echocardiograms. The valvular 
leaflet vibrational frequency (fmv ) can be obtained from the frequency spectra of the FHS 
phonocardiographic signal associated with MV movement.  
We can study a number of patients and determine the in vivo (E*,σ*) values of their valves, 
at a regular intervals during their degeneration process. We can also simultaneously and 
regularly monitor cardiac symptoms and chamber sizes and correlate them with the valcular 
constitutive E*- σ* property. By means of these correlations, we can determine the critical 
(E*- σ*) boundary at which intervention will have to be made to replace the degenerated 
natural valve by means of a prosthetic flexible leaflet MV. 
In an alternative somewhat simpler approach, the mitral valve constitutive property 
parameter m (equation 35) can be employed diagnostically to track the deterioration due to 
calcification of the MV, in terms of Δmaccording to the relationship:  
 ( ) ( )0 0 ;mn mnm m f f m q q∆ = ∂ ∂ ∆ + ∂ ∂ ∆  where in 2mf fν =  (38) 
www.intechopen.com
Physiological Nondimensional Indices in Medical Assessment: 
For Quantifying Physiological Systems and Analysing Medical Tests’ Data 865 
 so that: 0
0
4 2mn
mn
f qm
m f q
⎛ ⎞ ⎛ ⎞∆ ∆∆
= −⎜ ⎟ ⎜ ⎟⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠
, (39) 
 or, 
( ) 0
0
1 4 2mn
mn
m' m m f q
m f q
⎛ ⎞ ⎛ ⎞= + ∆ ∆ ∆
= + −⎜ ⎟ ⎜ ⎟⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠
 (40) 
Now at the time of occurrence of the first heart sound (FHS), the differential pressure or 
loading (q0) across the mitral valve is very small. Hence the change in pressure loading valve 
(Δq0), over the period of time of patient-tracking, will also be small compared to Δfmv, and 
hence can be neglected in equation (40).  
Hence from Eq. (39), we can compute 
 
4 m
m
fm
m f
⎛ ⎞∆∆
= ⎜ ⎟⎜ ⎟⎝ ⎠
 (41) 
to represent the change (Δm) in the parameter (m), by merely monitoring the change in 
frequency (Δfmv) with respect to its earlier value (fmv). 
9. Noninvasive determination of bone osteoporosis index (in terms of bone 
flexural stiffness) for osteoporosis detection 
Osteoporosis is a metabolic bone disease that is characterised by decreased bone mineral 
content and associated decreased in its mechanical strength. Thus, the osteoporotic bone is 
more prone to fracture. 
Noninvasive measurement methods for osteoporosis detection include single and dual 
beam photon absorptiometry and a comparatively low cost low-frequency mechanical 
vibration (resonance and impedance) method [1, 12]. The low-frequency impedance 
response curve of ( the first bending mode of ) ulna yields the resonant frequency (fr) value, 
which can be formulated in terms of the mechanical properties of the ulna bone, namely its 
bending stiffness (EI) and mass (M). It has been found that the difference between normal 
and osteoporotic bone is 20% in resonant frequency (fr) and 80% in bending stiffness EI [13].  
This is because fr  is the ratio of bone stiffness (EI) to mass (M), and in the pathologic 
osteoporotic condition both stiffness and mass decrease. Also, it has been shown that in 
fresh canine bone, the bending moment causing fracture has a correlation with EI  of r =0.96 
and with bone mineral content of r=0.90. Thus based on these results it appears that the ulna 
bending stiffness EI is a good indicator of bone fracture strength, which is diminished in 
osteoporosis. Now, both EI and M are contained in the expression for the natural frequency 
(fr) of ulna vibrations, which in turn can be obtain from its resonance frequency [14]. In 
order to determine the resonance frequency of the ulna bone, it can be simply supported at 
its extremities and a vibrating probe  pressed against the skin at the center of the forearm (as 
carried out by Steel and Gordon [14] and schematised in Fig. 8). The resonance frequency fr 
(= natural frequency fn  of vibration of ulna) is obtained from the recording of the 
acceleration response as a function of the frequency. 
If the bone is vibrating at an angular frequency p, the weight of the ulna bone per unit length is w 
radius of the ulna is R, and its length is ℓ, then the natural frequency fn of the vibrating ulna 
beam, with its mass concentrated in the middle is given by : 
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 ( )/2  / /2nf p g stpi δ pi= = √  (42) 
where δst, the maximum central deflection of the simply supported ulna bone, is given by 
 ( )4st w / 77EI   δ = `  (43) 
wherein w is the ulna weight per unit length. 
Hence, from (42) and (43), we get  
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By putting w = ρAg ρ: bone density, A: cross-sectional area, we get   
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where M is the mass of the ulna bone.  
By altering the frequency of the vibrating probe, we set the ulna into resonance, and the 
resonance frequency will be equal to the natural frequency. For fr resonance frequency = fn = 
400Hz, A = 50 × 10−4m2, I = 3 × 10−8m4, length (ℓ) = 0.17m, ρ = 1.8 × 103 kg/m3 , we get E = 20 
× 109 N/m2 and EI = 30Nm2. 
Thus, from equation (45), by modeling the ulna bone as a simply-supported vibrating beam, 
and determining its natural transverse-vibrational frequency (equal to its measured 
resonance frequency fr), we can measure its flexural stiffness EI, to detect osteoporosis. 
 
 
Fig. 8. Set-up used by Steel and Gordon [14] to determine the impedance of ulna. In this set 
up, the impedance head is attached to the moving element in the shaker. The probe, which 
contracts the skin, is attached to the impedance head. 
10. Cardiac assessment based on Myocardial infarct detection and Intra-
ventricular flow and pressure determination 
In cardiology, a primary disorder is that of a heart with infarcted myocardium. This 
infarcted myocardial wall mitigates adequate contraction of the wall. So, the end-result of an 
www.intechopen.com
Physiological Nondimensional Indices in Medical Assessment: 
For Quantifying Physiological Systems and Analysing Medical Tests’ Data 867 
infarcted left ventricle (LV) is poor intra-LV velocity distribution and pressure-gradient 
distribution, causing impaired outflow from the LV into the aorta. 
In the infarcted myocardial segments, the myocardial infrastructure of actin and myosin 
filaments (and their cross – bridges) is disrupted, and hence there is no contraction within 
these infarcted myocardial segments. Figure 9 [15] illustrates a myocardial sarcomere 
segment’s bioengineering model, composed of two symmetrical myocardial structural units 
(MSUs). In these MSU(s), the contractile elements represent the actin-myosin contractile 
components of the sarcomere segment. 
 
 
Fig. 9. Based on the conventional Hill three-element model and Huxley cross bridge theory, we 
have developed a myocardial model involving the LV myocardial mass, series-elastic element 
(CE). In this figure we have linked the anatomical associations of these myocardial model 
elements with microscopic structure of the heart muscle. This figure illustrates the sarcomere 
element contractile model, involving: the effective mass (m) of the muscle tissue that is 
accelerated; elastic parameter k of the series element stress σSE (k = elastic modulus of the 
sarcomere) viscous damping parameter B of the stress σVE  in the parallel viscous element VE, 
the generated contractile stress  σCE between myosin (thick ) and actin (thin ) filaments.  
The disruptions of these contractile elements impairs the contractile capability of that 
sarcomere segment. Hence, a LV with infarcted myocardial segments will have diminished 
contractility, inadequate and improper intra-LV flow, and poor ejection. 
Detection of myocardial infarcted segments: Now, infarcted myocardial segments can be 
detected as highly  reflectile echo zones (HREZs) in 2- dimensional B-scan echocardiograms. 
In this context, we have shown earlier [16] how infarcted myocardial segments can be 
detected (in shape and size), by echo-texture analysis, as highly reflectile echo zones or 
HREZs. Now, each tissue component of the heart generates a grey scale pattern or texture 
related to the tissue density and fibrous content, and hence tissue stiffness. 
In diseased states (such as myocardial ischemia, myocardial fibrosis, and infiltrative 
diseases), changes in myocardial tissue stiffness have been recognised by employing echo 
intensity and mean grey level of pixel as the basis for recognition of such myocardial 
disorders. It was found that hyper- reflectile echoes (HREs) correlated well with diseased 
cardiac muscle, and that myocardial tissue containing HREs corresponded with foci of sub 
endorcardial necrosis and even calcification.  
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In our earlier study [15], in order to determine highly reflectile echo zones (HREZs), 
echocardiograms were recorded; each image was made up of 256 x 256 pixels, with each 
pixel having a resolution of 0-256 grey scales. The echocardiographic images were digitised 
into 256 grey scales. Then, echo intensity levels from normal infants were used to delineate 
the range of echo intensities for normal tissues. The upper bound of the echo intensity was 
set to 100 per cent in each normal infant, and the intensities from the rest of the image was 
referenced to this level. Normally, pericardium had the highest intensity level. It was found 
that the upper- bound of the echo intensity value for healthy tissue (expressed as a 
percentage of the pericardial echo intensity value) was 54.2. 
 
 
Table 1. Echo intensity values for various anatomic regions of diseased pediatric hearts 
(based on long axis view). The numbers in the four rows represent Mean (M), Standard 
Deviation (SD), Number of Pixels (N), Percentage of Posterior Pericardial Intensity (P). 
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For patients whose echo-texture analysis showed presence of HREs, it was found that the 
echocardiographic intensities of the HREs from these patients intensities), were distinctly 
higher than the echo intensity range of normal tissue (as depicted in Table 1). 
Figure 10(a) depicts an echo image of an infant with visible scars regions 1 and 2, while 
figures 10(b) depict printouts of the echo intensities from these two regions, wherein the 
infarcted segments are depicted in dark colour. 
 
 
Fig. 10. (a) Long axis view of a pediatric patient’s heart showing HRE regions 1 and 2 and a 
healthy region 3.(Adopted from the author’s paper Ref 16). 
 
 
Fig. 10. (b) Pixel values corresponding to highly reflectile echo region 1. The central region 
having echo-intensity values greater than 200 is infarcted.  (Adopted from the author’s 
paper, Ref 16).  
Myocardial tissue pixels having echo-intensity values greater than 200 were designated to 
be infarcted. This infarcted sub-region is seen to be surrounded by an ischemic sub-region 
whose pixels have echo intensity values between 100 and 200. The surrounding healthy 
tissue has echo intensity less than 100. 
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In this way, in each highly reflectile echo zone (HREZ) made up of , say, N number of pixels, 
we can determine the number (I) of infarcted pixels. The ration I/N represents the infarcted 
potion of that HREZ myocardial segment. The total number of all the infarcted pixels in all 
the HREZs provides an indication of the amount of infarcted myocardium of the heart or of 
the LV. 
Intra-LV Blood Flow velocity and pressure distribution: Now, let us come to the outcome of an 
infarcted heart and LV. Figure 11 illustrates this outcome in the form of intra-LV blood-flow 
velocity and pressure (or pressure-gradient) distributions [17]. During LV diastole, from the 
monitored entrance velocity of blood at the mitral valve and the wall motion of the 
expanding LV, we can compute the intra-LV blood-flow velocity and pressure distributions, 
by computational fluid dynamics (CFD). During systole, from the monitored exit velocity or 
the aortic valve and the wall motion of the contracting LV, we can compute the intra-LV 
blood-flow velocity and pressure distribution by CFD. 
Figure 11 illustrates the computed intra-LV blood-flow velocity and pressure distribution of 
a patient with an infarcted myocardium, before and after administration of nitroglycerin to 
determine the viability of the myocardial wall following bypass surgery. Referring to Fig 11, 
for the patient (with a myocardial infarct), Figs. 11(a1) depict super-imposed LV outlines at 
known equal intervals during diastole and systole before nitroglycerin administration, and 
Figs 11 (a2) depict super-imposed LV outlines at known equal intervals during diastole and 
systole after nitroglycerin administration; nitroglycerin is a myocardial perfusing agent, and 
hence a quasi-simulator of coronary bypass surgery or coronary angioplasty.  From these 
images, we can determine the instantaneous wall displacements and hence the wall 
velocities at these time instants.  
This data, along with the monitored entrance and exit velocities of blood into and from the 
LV, constitutes the data for our CFD analysis.  For computational purposes, the intra-LV 
flow is determined from the boundary condition of LV wall-motion velocity and inlet/outlet 
blood flow velocity to the standard potential-flow equation . The intra-LV pressure 
gradient can then be computed from the Bernoulli equation for unsteady potential flow. 
Figures 11(b1) and 11 (c1) depict intra-LV blood-flow velocity distributions during diastole 
and systole, before nitroglycerin administrations. 
Figures 11(b2) and 11 (c2) depict intra-LV blood-flow velocity distributions during diastole 
and systole, after nitroglycerin administrations 
Figures 11(d1) and 11 (e1) depict intra-LV pressure distributions during diastole and systole, 
before nitroglycerin administrations 
Figures 11(d2) and 11 (e2) depict intra-LV pressure distributions during diastole and systole, 
after nitroglycerin administrations 
In this patient, the poor motion of the infarcted LV wall offers resistance to proper filling of 
the LV (Fig 11-b1). However, it can be noted that following the administration of 
nitroglycerin, there is improved filling of the LV (Fig. 11-b2). During systolic ejection phase, 
the infarcted LV wall segments do not contract, and this results in inadequate intra-LV flow 
velocity distribution, which mitigates adequate emptying of the LV (Fig 11-c1).  Following 
nitroglycerin administration, there is improved outflow velocity distribution. Likewise, 
figures (11-d1 and 11-e1) demonstrate adverse intra-LV pressure gradients during filling 
and ejection phases, which are improved after administration of nitroglycerin (Eq 11-d2 and 
11-e2). This has provided the basis for advocating coronary revascularization by coronary 
bypass surgery, for this patient.  
0
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The computed intra-LV blood-flow velocity and pressure distributions provide illustrative 
and quantitative outcome of an infarcted LV to the physician, which enables more distinct 
assessment of LV dysfunction.  The cause of this LV dysfunction is provided by the echo-
texture analysis of 2-d B-scan echocardiograms of HREZ(s), in terms of the amount (or 
number of echocardiogram image pixels) of the infarcted myocardial wall. Together, these 
two methodologies provide reliable and quantitative assessment of (i) how much of the LV 
myocardium is infarcted and its effect on the intra-LV blood flow and pressure- gradient, 
and (ii) intra-LV distributions of blood-flow velocity and pressure distributions, to assess 
candidacy for coronary bypass surgery.  
 
 
Fig. 11. (a,b,c) Patient TURN: (a) Superimposed sequential diastolic snd systolic endocardial 
frames (whose aortic valves centres and the long axis are matched) before (1) and after (2) 
administration of nitroglycerin. (b) Instantaneous intra-LV distributions of velocity during 
diastole, before (1) and after (2) administration of nitroglycerin. (c) Instantaneous LV 
distributions of velocity during ejection phase, before (1) and after (2) administration of 
nitroglycerin. (d) Instantaneous intra-LV distributions of pressure-differentials during 
diastole, before (1) and after (2) administration of nitroglycerin. (e) Instantaneous intra-LV 
distributions (pressure-differential) during ejection phase, before (1) and after (2) 
administration of nitroglycerin. 
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Fig. 11. (d,e) Patient TURN: (a) Superimposed sequential diastolic snd systolic endocardial 
frames(whose aortic valves centresand the long axis are matched) before (1) and after (2) 
administration of nitroglycerin. (b)Instantaneous intra-LV distributions of velocity during 
diastole, before (1) and after (2) administration of nitroglycerin. (c) Instantaneous LV 
distributions of velocity during ejection phase, before (1)and after (2) administration of 
nitroglycerin. (d) Instantaneous intra-LV distributions of pressure-differentials during 
diastole, before (1) and after (2) administration of nitroglycerin. (e) Instantaneous intra-LV 
distributions (pressure-differential) during ejection phase, before (1) and after (2) 
administration of nitroglycerin. 
d1 d2 
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11. Biomedical engineering concept of Heart Failure  
Heart Failure, in biomedical engineering (BME) terms, can imply failure of the heart to: 
i.   develop adequate contractility, due to a sizable amount of non-contractile infarcted 
myocardium (systolic heart failure)  
ii.   generate appropriate intra-LV pressure gradient during the ejection phase, to produce 
adequate LV outflow rate,  stroke volume and cardiac output; 
iii.   produce adequate pressure increase during isovolumic contraction and ejection phases, 
to overcome the aortic systolic pressure; 
iv.   effect adequate stroke volume, due to poor contractility (systolic heart failure) or poor 
filling due to diseased and stiff myocardium (diastolic heart failure).  
So the factors causing systolic heart failure may be summarized to be: 
1. excessive percentage amount of infarcted myocardium PMI (as determined by the  
procedure in section 10), 
2. resulting incapacity of the LV to produce appropriate intra-LV pressure gradient,  
for adequate LV outflow velocity and flow rate dV/dt (as determined by the 
methodology in section 10), as manifested by the contractility index CCI (formulated in 
section 2).  
Now the resultant dV/dt factor in item 2 is incorporated in the formula for CCI (equation 3).   
No doubt, the PMI affects CCI, but there is no direct formulation connecting these two 
indices. So we can state that PMI and CCI are the two parameters that can be attributed to 
the occurrence of heart failure.  
We can then define the Systolic Heart Failure index, as 
  ( ) ( ) ( )1 1in %  x in s / in sHFIN PMI HR CCI− −=   (46) 
Now, in order to assess the terminal value of HFIN, we need to determine the terminal 
values of PMI, CCI, and HR, by studying normal subjects (as these indices are noninvasively 
determinable) as well as patients in different stages of heart failure.   
Now, based on our studies (in Refs 4 & 5), let us (for the time being) adopt (i) the minimum 
acceptable value of CCI to be 3 s-1, (ii) the maximum acceptable value of PMI to be 15 %, and 
(iii) the maximum resting HR to be 120/min or 2 s-1. Substituting these values into equation 
(46) gives the terminal value of HFIN to be 10. In other words, if the value of HFIN exceeds 
the value 10, we can designate the patient to be in heart failure. 
12. Concluding remarks 
In this chapter, we have developed and presented noninvasive medical tests methodologies 
and associated NDPI(s), to make the case for reliable medical assessment of organ 
performance, physiological system function and dysfunction, anatomical structural property 
and pathology. The following tests and associated NDPI(s) have been presented: 
3. Determination of cardiac contractility, from measurement of LV chamber volume and 
myocardial volume, in terms of the cardiac contractility index CCI of (dσ*/dt)max, given 
by equation (3). 
4. Treadmill test to assess cardiac fitness and heart function, by means of the cardiac 
fitness index CFI, given by equation (8). 
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5. Lung Ventilation test, by monitoring lung volume by spirometry, for assessing lung 
ventilation and diagnosing lung disorders by means of lung ventilation index LVPI-2 
(equation 12). 
6. Oral Glucose Tolerance test, to more reliably diagnose diabetes, by determining the 
diabetes index DBI, given by equation (16). 
7. Noninvasive determination of arterial stiffness to detect arteriosclerosis, by 
ultrasound measurement of arterial dimensions and pulse wave velocity and 
auscultatory diastolic pressure, by means of the arteriosclerosis index ART-NPI, given 
by equation (20). 
8. Noninvasive determination of (i) Aortic Pressure profile and (ii) Aortic normal vs 
disease state property in terms of the Aortic number given by equation (31), by 
monitoring the left ventricular outflow into the aorta and auscultatory diastolic and 
systolic pressures. 
9. Noninvasive determination of Mitral valve pathology, by (i) monitoring its 
vibrational  frequency from the first heart sound spectrum, and its size parameter from 
2-d echocardiogram, and (ii) employing this data to structure its E* vs. σ*  constitutive 
property (equations 36 and 37), and determine the alteration in the value of the 
constitutive index m given by equation (40). 
10. Characterization of Osteoporosis, by determining the ulna bone vibratory resonance 
frequency, in terms of its flexural stiffness EI, given by equation (45). 
11. Quantitative determination of (i) the amount of infarcted myocardial segment of the 
heart from echo-texture analysis of 2-d echo cardiograms (figure 10), and  (ii) associated 
outcome of LV dysfunction in terms of the intra-LV blood-flow velocity and pressure 
distributions (figure 11). 
Together these tests and their associated NDPI (s) can provide more reliable medical assessment. 
What now needs to be done is (i) application of these tests to large patient populations, and (ii) 
determination of the ranges of NDPI (s) for normal and abnormal states of organs, physiological 
systems and anatomical structures.  
All of these tests can be employed in tertiary patient case, through the department of biomedical 
engineering (BME) in a tertiary-cave medical center. This makes a strong case for the institution of 
BME departments in tertiary case medical centers, which will revolution therapy health care.     
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